Uniqsis has published an application note that describes an efficient two-step synthesis of a library of pyrazoles under continuous flow-through conditions developed by chemists at GalChimia in Spain on a FlowSyn continuous flow reactor system.
Pyrazoles are an important and well represented chemotype in drug discovery displaying wide ranging biological actions that include analgesic, anti-inflammatory, antipyretic, tranquilising, muscle relaxing, anticonvulsant, antidiabetic and antibacterial activities. Their preparation typically involves condensation of a hydrazine with a 1,3-diketone or Michael acceptor.
The aim of the described work was to develop a new continuous flow protocol to replace the traditional two-step synthesis and to examine the scope of the new methodology. The authors of the application note demonstrate how using the FlowSyn system a range of conditions could be quickly evaluated under flow-through conditions thereby facilitating rapid reaction optimisation. In addition, using the FlowSyn system useful quantities of a wide range of pyrazoles could be prepared in less than one hour each.
Dr Jacabo Cruces, CEO of GalChimia commented: "Taking in account all the data we gathered in the different experiments, we can conclude that the tandem synthesis of pyrazoles using the Uniqsis FlowSyn system offers a general, high-yielding method to prepare these compounds, which can be used with many different substrates".
The FlowSyn is a compact integrated continuous flow reactor system designed for easy, safe and efficient operation. The FlowSyn range includes models for performing single or multiple homogeneous or heterogeneous reactions, either manually or automatically.
